The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.6M data for 1.1M Compounds and 8.10K Targets. Of those, 1,212K data for 559K Compounds and 4.4K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to you in 2022, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

29 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.EBI
Novartis Institutes for BioMedical Research
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).EBI
Icahn School of Medicine at Mount Sinai
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.EBI
Universit£ degli Studi di Parma
A quantitative analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.EBI
Ludwig-Maximilians University of Munich
Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.EBI
VU University Amsterdam
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).EBI
Ansaris
Comprehensive analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.EBI
Novartis Institute for BioMedical Research
Kinase Inhibition by Deoxy Analogues of the Resorcylic Lactone L-783277EBI
TBA
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI
Ambit Biosciences
Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).EBI
University of Zurich
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.EBI
GlaxoSmithKline
A small molecule-kinase interaction map for clinical kinase inhibitors.EBI
Ambit Biosciences
NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.EBI
University of California
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.EBI
Sichuan University
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.EBI
Beijing Normal University
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.EBI
Genomics Institute of the Novartis Research Foundation
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.EBI
Merck & Co.
Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.EBI
The Scripps Research Institute
Discovery of 4EBI
TBA
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.EBI
University of Florida
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.EBI
Takeda Pharmaceutical Company Limited
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.EBI
Novartis Institutes for Biomedical Research
Targeting Eph/ephrin system in cancer therapy.EBI
University of Parma
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.EBI
Vertex Pharmaceuticals Inc
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.EBI
Vertex Pharmaceuticals, Inc
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.EBI
Novartis Institutes for Biomedical Research
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.BDB
Case Western Reserve University